Peter Bojko

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

M. E. Scheulen, Ralf A. Hilger, C. Oberhoff et al. · PubMed · 2000 · 110 citations

Pharmacy, Oncology, Pharmacokinetics +16

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

Simon Mller, P. Sch�tt, Peter Bojko et al. · Annals of Hematology · 2004 · 65 citations

Medicine, Hematology, Internal Medicine +12

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

Philipp Schütt, Peter R. Ebeling, Ulrike Buttkereit et al. · European Journal Of Haematology · 2004 · 46 citations

Medicine, Oncology, Pharmacotherapy +17

Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients

Mohammad R. Nowrousian, S. R. Waschke, Peter Bojko et al. · Annals of Oncology · 2003 · 35 citations · Full text

Medicine, Hematology, Oncology +17